Nobivac®

Intra-Trac®3

A proven intranasal vaccine that provides triple protection against the agents implicated in the cause of tracheobronchitis (“canine cough”).

It’s time to Pair Up for Protection

INTRA-TRAC®3 PROVIDES PROTECTION AGAINST TRACHEOBRONCHITIS (“CANINE COUGH”)

Canine Adenovirus 2, Canine Parainfluenza Virus (modified live viruses), Bordetella Bronchiseptica (avirulent live culture).

  • Protects against Bordetella, canine parainfluenza virus, and canine adenovirus type
  • Offers the superior benefits of intranasal administrationCan be used in puppies as young as 3 weeks of age because maternal antibodies do not interfere with localized antibody response
  • Requires only single-nostril administration—low dose of 0.5 mL
  • Provides rapid protection beginning as early as 48 hours post-vaccination against B. bronchiseptica14
  • Proven 1-year duration of immunity for B. bronchiseptica15

INDICATIONS:

This product has been shown to be effective for vaccination of healthy dogs 3 weeks of age or older against canine adenovirus type 2, canine parainfluenza virus and Bordetella bronchiseptica.

Efficacy & Comparisons

INTRANASAL VS. ORAL AND INJECTABLE

NOBIVAC® INTRA-TRAC®3 INTRANASAL OFFERS ADVANTAGES OVER ORAL AND INJECTABLE VACCINES

*Dant JC, Waszgis B, LaFleur RL, Xu Z, Tarpey I. Duration of Immunity for an Oral Bordetella Bronchiseptica Vaccine. ISCAID Proceedings, Portland, OR, 2018.

NOBIVAC® INTRA-TRAC®3 EFFICACY

PROMOTES A STRONGER IGA RESPONSE THAN SUBCUTANEOUS VACCINATION16,17

  • IgA on mucosal surfaces appears to be more important than systemic responses when it comes to protecting against respiratory pathogens 18,19
    • Prevents microbes from adhering to mucosal surfaces of the nose and throat
    • Helps clear microbes trapped in mucus at the point of entry
  • Eliminated Bordetella shedding in controlled challenge 9 weeks after vaccination16
  • Significantly reduced cough scores and days of coughing16

No items to show.

Loading…

INTRA-TRAC®3 IS A SAFE CHOICE

  • Can be used in puppies as young as 3 weeks of age because maternal antibodies do not interfere with localized antibody response
  • Requires only single-nostril administration—low dose of 0.4–0.5 mL
  • Available with Advanced Delivery Technology (ADT) that eliminates the possibility of accidental injection (Nobivac® Intra-Trac® 3 ADT only)

ADMINISTRATION AND DOSAGE

  • Designed for intranasal use only with the enclosed applicators
  • Flexible dosing – For one 1 mL dose, rehydrate vaccine with 1 mL sterile diluent or for one 0.5 mL dose, rehydrate vaccine with 0.5 mL sterile diluent
  • Annual revaccination with 1 dose is recommended56
  • Available in a variety of presentations: 25 x 1, 2 x 5, and 150 x 1 dose

ALSO AVAILABLE IN OTHER FORMULATIONS

Professional Resources and Educational Materials

Keep your clinic and staff informed and aware of diseases and outbreaks.

Addressing CIV in Your Clinic 2020

eBook

Tips and guidelines for your clinic to prevent and manage canine influenza.  

Download

Pair Up for Protection

Infographic

When it comes to dogs in social environments, respiratory protection is essential. Use this conversation starter to discuss full respiratory protection with your clients.

Download

Pair Up for Protection Social Media Kit

Digital Assets

This vaccination season, use these ready-to-share posts to educate pet parents about the importance of full canine respiratory protection.  

Download

No items to show.

Loading…

References:

1. Data on file, Merck Animal Health. 

14. Bey RF, Shade FJ, Goodnow RA, Johnson RC. Intranasal vaccination of dogs with live avirulent Bordetella bronchiseptica: correlation of serum agglutination titer and the formation of secretory IgA with protection against experimentally induced infectious tracheobronchitis. Am J Vet Res. 1981;42(7):1130–1132. 

15. Lehr C, Jayappa H, Erskine J, Brown A, Sweeney D, Wasmoen T. Demonstration of 1-year of immunity for attenuated Bordetella bronchiseptica vaccines in dogs. Vet Ther. 2008;9(4):257–262. 

16. Davis R, Jayappa H, Abdelmagid OY, Armstrong R, Sweeney D, Lehr C. Comparison of the mucosal immune response in dogs vaccinated with either an intranasal avirulent live culture or a subcutaneous antigen extract vaccine of Bordetella bronchiseptica. Vet Ther. 2007;8(1):32–40. 

17. Information sheet: Canine: Infectious respiratory disease complex (aka “kennel cough”). UC Davis Koret Shelter Medicine Program website. Updated April 25, 2012. Available at: http://www.sheltermedicine.com/node/31. Accessed October 29, 2013. 

18. Cohn LA, Reinero CR. Respiratory defenses in health and disease. Vet Clin Small Anim. 2007;37(5):845–860. 

19. Greene CE, ed. Infectious Diseases of the Dog and Cat. 4th ed. St. Louis, MO: Elsevier; 2012. 

56. AAHA Canine Vaccination Guidelines (Revised 2017). https://www.aaha.org/guidelines/canine_vaccination_guidelines/practice_vaccination.aspx. Accessed July 26, 2018.

View All Nobivac References